HK1208376A1 - Artificial antigen presenting cell for preparing cd8 cell suspension for use in the treatment of cancer cd8 - Google Patents

Artificial antigen presenting cell for preparing cd8 cell suspension for use in the treatment of cancer cd8

Info

Publication number
HK1208376A1
HK1208376A1 HK15109174.2A HK15109174A HK1208376A1 HK 1208376 A1 HK1208376 A1 HK 1208376A1 HK 15109174 A HK15109174 A HK 15109174A HK 1208376 A1 HK1208376 A1 HK 1208376A1
Authority
HK
Hong Kong
Prior art keywords
cells
artificial antigen
specific
cancer
antigen
Prior art date
Application number
HK15109174.2A
Other languages
English (en)
Chinese (zh)
Inventor
Juli Degraw
Ann Moriarty
Didier J Leturcq
Michael R Jackson
Per A Peterson
Marja Heiskala
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of HK1208376A1 publication Critical patent/HK1208376A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464491—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0601—Invertebrate cells or tissues, e.g. insect cells; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK15109174.2A 2001-02-20 2015-09-18 Artificial antigen presenting cell for preparing cd8 cell suspension for use in the treatment of cancer cd8 HK1208376A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27025201P 2001-02-20 2001-02-20

Publications (1)

Publication Number Publication Date
HK1208376A1 true HK1208376A1 (en) 2016-03-04

Family

ID=23030546

Family Applications (2)

Application Number Title Priority Date Filing Date
HK04101353A HK1058485A1 (en) 2001-02-20 2004-02-25 A cell therapy method for the treatment of tumors
HK15109174.2A HK1208376A1 (en) 2001-02-20 2015-09-18 Artificial antigen presenting cell for preparing cd8 cell suspension for use in the treatment of cancer cd8

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK04101353A HK1058485A1 (en) 2001-02-20 2004-02-25 A cell therapy method for the treatment of tumors

Country Status (22)

Country Link
US (2) US20030077248A1 (xx)
EP (3) EP1377251B1 (xx)
JP (3) JP2006510567A (xx)
KR (2) KR100971266B1 (xx)
CN (1) CN1571834B (xx)
AT (1) ATE396691T1 (xx)
BR (1) BR0207399A (xx)
CA (2) CA2698079C (xx)
DE (1) DE60226853D1 (xx)
DK (1) DK2016930T3 (xx)
EA (1) EA013944B1 (xx)
ES (2) ES2643582T3 (xx)
HK (2) HK1058485A1 (xx)
HU (1) HUP0402656A3 (xx)
IL (3) IL157366A0 (xx)
MX (1) MXPA03007503A (xx)
NO (1) NO334885B1 (xx)
NZ (1) NZ527683A (xx)
PL (1) PL206976B1 (xx)
PT (1) PT1377251E (xx)
WO (1) WO2002065992A2 (xx)
ZA (1) ZA200307327B (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973137B1 (en) 1996-03-28 2011-07-05 Johns Hopkins University Cell compositions comprising molecular complexes that modify immune responses
ES2643582T3 (es) 2001-02-20 2017-11-23 Janssen Pharmaceuticals, Inc. Antígeno de Drosophila artificial que presenta célula para preparar suspensión de células CD8 para su uso en el tratamiento del cáncer
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
CA2440610C (en) * 2001-03-09 2011-07-12 Board Of Regents, The University Of Texas System Induction of tumor immunity by variants of folate binding protein
WO2003076585A2 (en) * 2002-03-08 2003-09-18 Board Of Regents, The University Of Texas System Controlled modulation of amino acid side chain length of peptide antigens
WO2004006951A1 (en) * 2002-07-12 2004-01-22 The Johns Hopkins University Reagents and methods for engaging unique clonotypic lymphocyte receptors
EP1558723A4 (en) * 2002-11-07 2006-02-15 Johnson & Johnson Res Pty Ltd MEANS FOR THE PREPARATION AND USE OF A POPULATION OF DISEASE-SPECIFIC CYTOTOXIC T-LYMPHOCYTES
EP1645183B1 (en) * 2003-06-16 2013-03-13 Kyushu University, National University Corporation Process for producing human-origin immunocompetent cell
JP2005139118A (ja) * 2003-11-07 2005-06-02 Ortho Mcneil Pharmaceut Inc 腫瘍の治療のための細胞治療方法
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
WO2008039874A2 (en) 2006-09-26 2008-04-03 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008039969A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
CA2665568C (en) 2006-10-04 2018-01-09 Janssen Pharmaceutica, N.V. Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
PL2328923T3 (pl) 2008-09-02 2016-06-30 Cedars Sinai Medical Center Epitopy CD133
JP2010235611A (ja) * 2010-05-10 2010-10-21 Ortho Mcneil Pharmaceut Inc 腫瘍の治療のための細胞治療方法
WO2012087943A2 (en) * 2010-12-20 2012-06-28 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
CA2898474A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
CN103667189B (zh) * 2013-09-24 2015-10-28 上海宇研生物技术有限公司 用于治疗肺癌的cd8毒性t淋巴细胞及其制备方法
MX2017003625A (es) * 2014-09-17 2017-10-11 Univ Johns Hopkins Reactivos y metodos para identificar, enriquecer y/o expander celulas t especificas de antigeno.
US9993538B2 (en) 2015-05-29 2018-06-12 Galena Biopharma, Inc. Peptide vaccine therapy for treatment of FRα-expressing tumors
WO2017210255A1 (en) 2016-05-31 2017-12-07 Galena Biopharma, Inc. Vaccine therapy for treatment of endometrial and ovarian cancer
WO2017216768A1 (en) 2016-06-16 2017-12-21 Association For The Advancement Of Tissue Engineering And Cell Based Technologies And Therapies - A4Tec Dendrimer-derived artificial antigen, methods and uses thereof
AU2017305396A1 (en) * 2016-08-02 2019-02-21 Nant Holdings Ip, Llc Transfection of dendritic cells and methods therefor

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530901A (en) * 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4401756A (en) * 1981-04-14 1983-08-30 Immunex Corporation Process for preparing human interleukin 2
US4473642A (en) * 1981-04-29 1984-09-25 Immunex Corporation Constitutive production of interleukin 2 by a T cell hybridoma
US4407945A (en) * 1981-04-29 1983-10-04 Immunex Corporation Constitutive production of interleukin 2 by a T cell hybridoma
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4992367A (en) * 1986-05-12 1991-02-12 Hoffmann-La Roche Inc. Enhanced expression of human interleukin-2 in mammalian cells
US5229115A (en) * 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US5583031A (en) * 1992-02-06 1996-12-10 President And Fellows Of Harvard College Empty major histocompatibility class II heterodimers
US5314813A (en) 1992-02-19 1994-05-24 Scripps Research Institute Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines
US5731160A (en) 1992-05-26 1998-03-24 Rijksuniversiteit Leiden Induction of antigen specific T-lymphocyte responses by stimulation with peptide loaded MHC class I molecules on antigen processing defective mammalian cell lines
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5662907A (en) * 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
US5487974A (en) 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5820866A (en) * 1994-03-04 1998-10-13 National Jewish Center For Immunology And Respiratory Medicine Product and process for T cell regulation
US5585461A (en) * 1994-03-24 1996-12-17 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US5968753A (en) 1994-06-14 1999-10-19 Nexell Therapeutics, Inc. Positive and positive/negative cell selection mediated by peptide release
US5595881A (en) 1994-08-09 1997-01-21 Anergen, Inc. Method for the detection of antigen presenting cells
US5827642A (en) * 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5843648A (en) * 1995-01-10 1998-12-01 The United States Of America As Represented By The Secretary, Department Of Health And Human Services P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
US5645837A (en) * 1995-01-17 1997-07-08 Thomas Jefferson University Peptides that inhibit T cell activation and methods of using the same
DE69628154T2 (de) * 1995-03-08 2004-03-18 The Scripps Research Institute, La Jolla Antigen präsentierendes system und aktivierung von t-zellen
US5759783A (en) 1995-03-14 1998-06-02 Ludwig Institute For Cancer Research Method of screening for cancer by detecting messenger RNA for a MAGE-XP gene
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
US5695760A (en) 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
CA2247131A1 (en) 1996-03-04 1997-09-12 Targeted Genetics Corporation Modified rapid expansion methods ("modified-rem") for in vitro propagation of t lymphocytes
ATE347588T1 (de) * 1996-05-23 2006-12-15 Scripps Research Inst Systeme zur präsentation von mhc-antigenen der klasse ii und verfahren zur aktivierung von cd4?+-t-lymphozyten
WO2001059073A2 (en) * 2000-02-11 2001-08-16 Dana-Farber Cancer Institute, Inc. Cytotoxic t lymphocytes activated by dendritic cell hybrids
EP1071436A4 (en) * 1998-01-26 2003-08-27 Dana Farber Cancer Inst Inc IMMUNE EFFECTOR CELL HYBRIDS
WO1999054345A1 (en) 1998-04-21 1999-10-28 Thomas Jefferson University Cd8 antagonists
US6140050A (en) * 1998-06-26 2000-10-31 Ludwig Institute For Cancer Research Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
WO2000063690A1 (en) * 1999-04-16 2000-10-26 Ortho-Mcneil Pharmaceutical, Inc. Enriched antigen-specific t-cells, and related therapeutic and prophylactic compositions and methods
JP2001089389A (ja) 1999-07-22 2001-04-03 Sumitomo Pharmaceut Co Ltd 抗原特異的ｔ細胞の誘導剤
WO2001057068A1 (en) * 2000-02-01 2001-08-09 The Austin Research Institute Mucin-1 derived antigens and their use in immunotherapy
WO2002004603A2 (de) * 2000-07-10 2002-01-17 Eppendorf Ag Verfahren zur modifizierung von biologischen zellen
ES2643582T3 (es) 2001-02-20 2017-11-23 Janssen Pharmaceuticals, Inc. Antígeno de Drosophila artificial que presenta célula para preparar suspensión de células CD8 para su uso en el tratamiento del cáncer

Also Published As

Publication number Publication date
IL219223A0 (en) 2012-06-28
CA2438754A1 (en) 2002-08-29
KR20090061081A (ko) 2009-06-15
ZA200307327B (en) 2005-03-30
US20030077248A1 (en) 2003-04-24
US20090305418A1 (en) 2009-12-10
EA200300815A1 (ru) 2004-06-24
US9222071B2 (en) 2015-12-29
DE60226853D1 (de) 2008-07-10
EA013944B1 (ru) 2010-08-30
IL219223B (en) 2018-05-31
EP2848255A1 (en) 2015-03-18
PL206976B1 (pl) 2010-10-29
NZ527683A (en) 2006-06-30
KR100962544B1 (ko) 2010-06-14
ES2643582T3 (es) 2017-11-23
ES2306771T3 (es) 2008-11-16
EP2848255B1 (en) 2017-08-23
JP2012097117A (ja) 2012-05-24
NO20033674L (no) 2003-10-17
HK1058485A1 (en) 2004-05-21
EP1377251A2 (en) 2004-01-07
PT1377251E (pt) 2008-08-05
WO2002065992A2 (en) 2002-08-29
HUP0402656A2 (hu) 2005-03-29
HUP0402656A3 (en) 2012-03-28
BR0207399A (pt) 2004-10-26
DK2016930T3 (en) 2014-12-08
CN1571834A (zh) 2005-01-26
EP1377251B1 (en) 2008-05-28
CA2438754C (en) 2014-10-07
NO334885B1 (no) 2014-06-30
ATE396691T1 (de) 2008-06-15
EP2016930A2 (en) 2009-01-21
JP5634415B2 (ja) 2014-12-03
EP2016930A3 (en) 2009-09-02
KR100971266B1 (ko) 2010-07-20
JP2006510567A (ja) 2006-03-30
EP1377251A4 (en) 2006-01-11
PL369971A1 (en) 2005-05-02
EP2016930B1 (en) 2014-10-15
KR20030077029A (ko) 2003-09-29
NO20033674D0 (no) 2003-08-19
MXPA03007503A (es) 2004-10-15
WO2002065992A3 (en) 2003-02-13
CN1571834B (zh) 2013-03-20
CA2698079A1 (en) 2002-08-29
JP2010222352A (ja) 2010-10-07
IL157366A (en) 2013-04-30
IL157366A0 (en) 2004-02-19
CA2698079C (en) 2015-01-13

Similar Documents

Publication Publication Date Title
HK1208376A1 (en) Artificial antigen presenting cell for preparing cd8 cell suspension for use in the treatment of cancer cd8
EP1470821A3 (en) Cell therapy method for the treatment of tumours
Vatakis et al. Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells
Wennhold et al. CD40-activated B cells induce anti-tumor immunity in vivo
Mukherji Immunology of melanoma
Hoyer et al. Concurrent interaction of DCs with CD4+ and CD8+ T cells improves secondary CTL expansion: It takes three to tango
ATE491465T1 (de) Verfahren zur gewinnung aktivierter t-zellen und mit antigen-inkubierten antigen-präsentierender zellen
CN101663047A (zh) 通过激活或阻断HLA-E/Qa-1限制性CD8+T细胞调控途径来治疗免疫疾病的方法
Sakaguchi et al. Immunologic self tolerance maintained by T-cell-mediated control of self-reactive T cells: implications for autoimmunity and tumor immunity
Wentworth et al. In vitro induction of primary, antigen-specific CTL from human peripheral blood mononuclear cells stimulated with synthetic peptides
WO2000076320A1 (en) Generation of antigen specific t suppressor cells for treatment of rejection
Roncarolo et al. Type 1 T regulatory cells and their relationship with CD4+ CD25+ T regulatory cells
CY1110235T1 (el) Χρηση αλλογενετικων κυτταρικων γραμμων για τη φορτωση κυτταρων που εμφανιζουν αντιγονο για την προκληση ή εξαλειψη ανοσολογικων απαντησεων
Laumbacher et al. Activated monocytes prime naïve T cells against autologous cancer: vigorous cancer destruction in vitro and in vivo
US20030082163A1 (en) Fused cells, methods of forming same, and therapies utilizing same
Schaft et al. CD8+ T-cell priming and boosting: more antigen-presenting DC, or more antigen per DC?
Sioud Does our current understanding of immune tolerance, autoimmunity, and immunosuppressive mechanisms facilitate the design of efficient cancer vaccines?
Mortara et al. Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions
Gritzapis et al. Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice
Carlier et al. Increased synapse formation obtained by T cell epitopes containing a CxxC motif in flanking residues convert CD4+ T cells into cytolytic effectors
Bolli et al. Oncoantigens for an immune prevention of cancer
Pancholi et al. An approach to isolating T cell lines that react to antigens presented on the surface of dendritic cells
Jang et al. Simultaneous expression of allogenic class II MHC and B7. 1 (CD80) molecules in A20 B-lymphoma cell line enhances tumor immunogenicity
Noyan et al. Naive Tumour‐Specific CD4+ T Cells were Efficiently Primed in Acute Lymphoblastic Leukaemia
Cheng et al. Induction of tumor-specific T cell response by cognating tumor cells with foreign antigen-primed Th cells.

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20220218